ArticleGynecologic oncology reports2025
Exploratory study of a long-term hospital-based cervical cancer screening program in a high HIV prevalence area of rural Malawi.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Malawi has the second-highest incidence and highest cervical cancer-attributed mortality worldwide. National HIV prevalence is 7.7%. Malawi implemented the Cervical Cancer Control Plan in 1999. We conducted an exploratory study of a non-government, hospital-based cervical cancer screening program established in the Southern Region. Methods: We performed a retrospective review of outcomes from a cervical cancer screening program at a 275-bed rural mission hospital from 1/2016 - 12/2021. Female patients 18 years and older presenting for cervical cancer screening were included. Outcomes included trends in screening modality, return screening rates, abnormal screening rates, and the COVID pandemic impact. Data abstracted included demographics, HIV status, screening modality, and follow-up information. Results: 15,432 patients were screened for cervical cancer during the study period, with an overall increase in annual number of patients screened, despite the COVID-19 pandemic. Screening was initially performed via Pap testing; Visual inspection with acetic acid became the most common screening modality in 2019 (69.4%).HIV prevalence among screened patients increased over the study period to 82.0% in 2021 and was higher among return screening patients (89.0%). 4.3% of HIV-negative and 7.2% of HIV-positive women demonstrated abnormal screening results. Conclusion: Despite the COVID-19 pandemic, the number of patients screened for cervical cancer annually increased over the study period. HIV prevalence in this study was much higher than the national prevalence. These results emphasize the successful collaboration between a national program, private hospital, and HIV treatment centers, and highlight the need to increase screening among healthy women in the community.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.